RE:RE:RE:RE:RE:Profitability of US Assets ex Impairments and debt chargesO Brien oversaw sales in the US until very recently.
Currently, sitavig is only sold to Dermatologists which are the most concentrated prescribers but represent the lowest volume.
Dentists and obstetricians/gynecologists are high prescribers with big volume groups. General practitioners are also high prescribers.
Yet O Brien kept sitavig sales focussed exclusively on dermatologists in the U.S., Sitavig generated $2M in revenues in 2016.
Cipher has been targetting $110M by 2020.
Refocussing their detail salesmen towards dentists, gynecologists and GPs, all with high volume prescribers ( about 15 times higher ), it becomes apparent that sitavig sales could reach $30 million by a simple extension of the sales practises to enclude ALL prescribing physicians.
Why O brien was late to the plate on this move was surely his responsibility.
The new BOD certainly has more heft, so they may just introduce growth in these US assets that was not obvious in 2015/16.